|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2a, kappa|
|Immunogen||Recombinant protein derived from the C-terminal region of the human MLH1 protein|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Immunohistochemistry (IHC)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MLH1 is a DNA mismatch repair protein. The repair of mismatch DNA is essential to maintaining the integrity of genetic information over time. An alteration of microsatellite repeats is the result of slippage owing to strand misalignment during DNA replication and is referred to as microsatellite instability (MSI). These defects in DNA repair pathways have been related to human carcinogenesis. The importance of mismatch repair genes became apparent with the identification of the genetic basis for hereditary nonpolyposis colon cancer (HNPCC). MSHS2 is involved in the initial cognition of mismatch nucleotides during the replication mismatch repair process. It is thought that after MSH2 binds to a mismatched DNA duplex it is joined by a heterodimer of MLH1 and PMSH, which together help facilitate the later steps in mismatch repair.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Human||1:200||Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung.||Gomes A,Reis-Silva M,Alarcão A,Couceiro P,Sousa V,Carvalho L||Revista portuguesa de pneumologia (20:20)||2014|
|Human||1:80||Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer.||Al-Temaimi RA,Jacob S,Al-Ali W,Thomas DA,Al-Mulla F||The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (61:627)||2013|
Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
39-3200 was used in immunohistochemistry - paraffin section to assess the use of the estrogen and progesterone receptors as prognostic factors in endometrioid endometrial adenocarcinoma.
|Huvila J,Talve L,Carpén O,Edqvist PH,Pontén F,Grénman S,Auranen A||Gynecologic oncology (130:463)||2013|